ABSTRACT
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia, bone mineralization disorders with increased risk of fragility fractures, muscle pain, and progressive weakness. TIO has been associated with increased production of the phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) usually by mesenchymal tumors of soft tissue or bone (Phosphaturic Mesenchymal Tumors-PMTs). In rare cases TIO may be observed in association with other malignancies. We report the case of a 66-year-old woman with an occasional diagnosis of both a PMT and an ovarian cancer during the evaluation of TIO. We also systematically review the literature to discover possible correlations between osteomalacia, FGF23 production, and ovarian cancer. Four studies were eligible for the analysis. Two case reports described an association between TIO development and ovarian cancer, whereas the two case-control studies hypothesized a possible correlation between FGF/FGF receptor axis and cancer development. Although it does not provide conclusive evidence regarding the association between TIO and ovarian cancer, this case report highlights the possibility that in the diagnostic workup of suspected TIO, both FGF23-secreting tumors distinct from PMT and tumors unrelated to the clinical presentation of TIO could be identified. This information is important for guiding successful tumor staging and determining the necessity for surgical intervention and/or eventual adjuvant therapy.
Subject(s)
Fibroblast Growth Factor-23 , Fibroblast Growth Factors , Osteomalacia , Ovarian Neoplasms , Paraneoplastic Syndromes , Humans , Female , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Aged , Paraneoplastic Syndromes/etiology , Paraneoplastic Syndromes/diagnosis , Fibroblast Growth Factors/blood , Fibroblast Growth Factors/metabolism , Neoplasms, Connective Tissue/diagnosis , Neoplasms, Connective Tissue/complications , Neoplasms, Connective Tissue/etiology , Hypophosphatemia/etiology , Hypophosphatemia/complicationsABSTRACT
OBJECTIVES: Tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR) is used to evaluate renal phosphate reabsorption and it is a useful tool for the differential diagnosis of hypophosphatemic syndromes. TmP/GFR is typically calculated from fasting plasma and second morning void urine samples, obtained 2â¯h after the first void (TmP/GFR 2â¯h). The purpose of this study was to evaluate if TmP/GFR calculated from 24â¯h urine collection (TmP/GFR 24â¯h) can be used as an alternative for TmP/GFR 2â¯h in patients with urine phosphate wasting. METHODS: We enrolled adult patients with X-linked hypophosphatemia (XLH) or tumor-induced osteomalacia (TIO). All patients underwent blood and urine sample collections, to calculate TmP/GFR 24â¯h and TmP/GFR 2â¯h. RESULTS: Twenty patients (17 XLH and 3 TIO), aged 24-78 years, were included. All patients had low TmP/GFR 2â¯h (0.35â¯mmol/L, IQR 0.24-0.47â¯mmol/L) and TmP/GFR 24â¯h (0.31â¯mmol/L, IQR 0.22-0.43â¯mmol/L). The concordance correlation coefficient between TmP/GFR 2â¯h and TmP/GFR 24â¯h was 0.86 (95â¯% CI: 0.69-0.93), with a systematic bias of 0.05â¯mmol/L (95â¯% limits of agreement: -0.10 to 0.20). Furthermore, in 70â¯% (i.e., 14 patients out of 20) and 80â¯% (i.e., 16 patients out of 20) of cases the difference between TmP/GFR 2â¯h and TmP/GFR 24â¯h was within ±30â¯% and ±35â¯%, respectively. CONCLUSIONS: Despite TmP/GFR 2 and 24â¯h show a relatively suboptimal agreement, the difference between the two parameters appears to be small and not clinically significant in the setting of adult patients with FGF23-dependent urine phosphate wasting and secondary hypophosphatemia.
Subject(s)
Fibroblast Growth Factor-23 , Osteomalacia , Phosphates , Urine Specimen Collection , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Familial Hypophosphatemic Rickets/urine , Familial Hypophosphatemic Rickets/diagnosis , Glomerular Filtration Rate , Hypophosphatemia/urine , Hypophosphatemia/diagnosis , Kidney Tubules/metabolism , Osteomalacia/urine , Osteomalacia/diagnosis , Paraneoplastic Syndromes/urine , Paraneoplastic Syndromes/diagnosis , Phosphates/urine , Urine Specimen Collection/methodsABSTRACT
Hepatitis C-associated osteosclerosis (HCAO) is a very rare condition that can be observed in a small number of patients with Hepatitis C Virus (HCV) infection. HCAO is usually characterized by widespread bone sclerosis, associated with severe bone pain, and increased levels of bone turnover markers, especially alkaline phosphatase (ALP). In this report, we present the case of a 55-year-old woman who was affected by HCV and came to our attention for severe and diffuse bone pain. Radiological studies showed bone sclerosis, and bone mineral density (BMD) was markedly increased, as well as serum ALP levels. The patient was initially treated with intravenous pamidronate, which provided only a transient benefit on clinical symptoms. Then antiviral therapy for HCV (interferon-alfa and ribavirin) was started and it was effective in making the viral load undetectable. After a long follow-up period, we observed a persistent remission of bone pain, a reduction in BMD together with a progressive trend toward the normalization of bone turnover markers. In conclusion, HCAO, although rare, should be considered among the potential causes of increased bone mass in patients with HCV infection, and treatment for the underlying infection may be effective in controlling the manifestations of this disease.
Subject(s)
Hepatitis C , Osteosclerosis , Female , Humans , Middle Aged , Antiviral Agents/therapeutic use , Follow-Up Studies , Hepacivirus , Hepatitis C/complications , Hepatitis C/drug therapy , Osteosclerosis/etiology , Osteosclerosis/complications , Pain/complications , Sclerosis/complications , Sclerosis/drug therapyABSTRACT
Currently available antidiabetic treatments fail to halt, and may even exacerbate, pancreatic ß-cell exhaustion, a key feature of type 2 diabetes pathogenesis; thus, strategies to prevent, or reverse, ß-cell failure should be actively sought. The serine threonine kinase Akt has a key role in the regulation of ß-cell homeostasis; among Akt modulators, a central role is played by pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) family. Here, taking advantage of an in vitro model of chronic exposure to high glucose, we demonstrated that PHLPPs, particularly the second family member called PHLPP2, are implicated in the ability of pancreatic ß cells to deal with glucose toxicity. We observed that INS-1 rat pancreatic ß cell line maintained for 12-15 passages at high (30 mM) glucose concentrations (INS-1 HG) showed increased expression of PHLPP2 and PHLPP1 both at mRNA and protein level as compared to INS-1 maintained for the same number of passages in the presence of normal glucose levels (INS-1 NG). These changes were paralleled by decreased phosphorylation of Akt and by increased expression of apoptotic and autophagic markers. To investigate if PHLPPs had a casual role in the alteration of INS-1 homeostasis observed upon chronic exposure to high glucose concentrations, we took advantage of shRNA technology to specifically knock-down PHLPPs. We obtained proof-of-concept evidence that modulating PHLPPs expression may help to restore a healthy ß cell mass, as the reduced expression of PHLPP2/1 was accompanied by a recovered balance between pro- and antiapoptotic factor levels. In conclusion, our data provide initial support for future studies aimed to identify pharmacological PHLPPs modulator to treat beta-cell survival impairment. They also contribute to shed some light on ß-cell dysfunction, a complex and unsatisfactorily characterized phenomenon that has a central causative role in the pathogenesis of type 2 diabetes.
ABSTRACT
Context: Type 2 diabetes (T2DM) is associated with a higher intestinal expression of the glucose transporters sodium/glucose cotransporter 1 (SGLT-1) and glucose transporter 2 (GLUT-2). It is currently unsettled whether prediabetes conditions characterized by postprandial hyperglycemia, such as impaired glucose tolerance (IGT) and normal glucose tolerance (NGT) with 1-hour postload glucose ≥155 mg/dL (8.6 mmol/L) (NGT-1h-high) are associated with increased expression of these glucose carriers in the intestine. Objective: We evaluated whether duodenal abundance of SGLT-1 and GLUT-2 is augmented in subjects with IGT and NGT-1h-high, in comparison with subjects with NGT and 1-hour postload glucose Ë155 mg/dL (NGT-1h-low). Design: Cross-sectional. Patients: A total of 54 individuals underwent an upper gastrointestinal endoscopy. Main Outcome Measures: Duodenal SGLT-1 and GLUT-2 protein and messenger RNA levels were assessed by Western blot and reverse transcription polymerase chain reaction, respectively. Results: Of the 54 subjects examined, 18 had NGT-1h-low, 12 had NGT-1h-high, 12 had IGT, and 12 had T2DM. Duodenal SGLT-1 protein and messenger RNA levels were significantly higher in individuals with NGT-1h-high, IGT, or T2DM in comparison with NGT-1h-low subjects. GLUT-2 abundance was higher in individuals with T2DM in comparison with NGT-1h-low subjects; no substantial increase in GLUT-2 expression was observed in NGT-1h-high or IGT individuals. Univariate correlations showed that duodenal SGLT-1 abundance was positively correlated with 1-hour postload plasma glucose levels (r = 0.44; P = 0.003) but not with fasting or 2-hour postload glucose levels. Conclusions: Duodenal SGLT-1 expression is increased in individuals with 1-hour postload hyperglycemia or IGT, as well as in subjects with T2DM, and it positively correlates with early postload glucose excursion.
Subject(s)
Duodenum/metabolism , Fasting/metabolism , Hyperglycemia/genetics , Sodium-Glucose Transporter 1/genetics , Adult , Aged , Cross-Sectional Studies , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Female , Glucose Intolerance/complications , Glucose Intolerance/genetics , Glucose Intolerance/metabolism , Glucose Tolerance Test , Glucose Transporter Type 2/genetics , Glucose Transporter Type 2/metabolism , Humans , Hyperglycemia/complications , Hyperglycemia/metabolism , Male , Middle Aged , Postprandial Period , Prediabetic State/complications , Prediabetic State/genetics , Prediabetic State/metabolism , Sodium-Glucose Transporter 1/metabolismABSTRACT
AIMS: We hypothesized that a disproportionate activation of the glucosamine (GlcN) pathway, caused by a prolonged exposure to hyperglycaemia, could impair endothelial integrity promoting endoplasmic reticulum (ER) stress. We also tested the possibility that SRT1720 may be able to counteract GlcN-induced ER stress. METHODS AND RESULTS: Human umbilical vein endothelial cells (HUVECs), human cardiac microvascular endothelial cells, and human retinal endothelial cells were treated with GlcN in the presence or absence of the chemical chaperone phenyl butyric acid (PBA) or SRT1720. Expression of ER stress markers, activation of apoptosis, and pro-inflammatory/pro-thrombotic pathways were evaluated by western blot, real-time RT-PCR, and ELISA assays. GlcN treatment resulted in a significantly increased expression of the major ER stress mediators. ER stress activation was paralleled by increased levels of apoptotic markers and by pro-inflammatory/pro-coagulant pathway activation. In HUVECs, ER stress inhibition by PBA alleviated a GlcN-induced pro-apoptotic and pro-inflammatory/pro-thrombotic state, suggesting a crucial role of ER stress in endothelial dysfunction caused by GlcN. Furthermore, SRT1720 treatment abolished GlcN-induced ER stress and reversed its effects on apoptosis and pro-inflammatory/pro-coagulant pathways. This SRT1720 action was mediated by its ability to modulate Raptor acetylation, thus inhibiting mammalian target of Rapamycin complex 1 (mTORC1)-dependent protein synthesis and alleviating ER overload. CONCLUSIONS: Our data show that GlcN promotes a pro-apoptotic and pro-inflammatory/pro-thrombotic phenotype in endothelial cells by activating ER stress. The observation that SRT1720, inhibiting ER stress, was able to counteract GlcN effects lays the basis for future studies aimed to exploit this drug and cognate compounds in the treatment of endothelial dysfunction and atherosclerosis.